BioWorld

Feb. 15, 2002

NeoGenesis, Aventis Pharma In Multiyear Infectious Disease Deal

NeoGenesis Pharmaceuticals Inc. said Thursday it will use its chemical genomics technologies to identify therapeutic agents for infectious diseases in a multiyear collaboration with Aventis Pharma SA. (BioWorld Today) Read More

Waiting For The FDA, NaPro Adds $16M To Cash Position

OmniScience, Ibis To Combine Technologies For Drug Discovery

Beyond Genomics’ Series B Raises $11M For Drug Discovery

Holiday Notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 17, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Illustration of cell receptors, antibodies

Abbvie and Simcere enter a $1B T-cell engager deal

BioWorld Asia

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...